Browsing by author "Jones, Chris"
Now showing items 41-54 of 54
-
PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.
Khadka, P; Reitman, ZJ; Lu, S; Buchan, G; Gionet, G; et al. (NATURE PORTFOLIO, 2022-02-01)The role of PPM1D mutations in de novo gliomagenesis has not been systematically explored. Here we analyze whole genome sequences of 170 pediatric high-grade gliomas and find that truncating mutations in PPM1D that increase ... -
PPM1D mutations silence NAPRT gene expression and confer NAMPT inhibitor sensitivity in glioma.
Fons, NR; Sundaram, RK; Breuer, GA; Peng, S; McLean, RL; et al. (NATURE RESEARCH, 2019-08-22)Pediatric high-grade gliomas are among the deadliest of childhood cancers due to limited knowledge of early driving events in their gliomagenesis and the lack of effective therapies available. In this study, we investigate ... -
Quantification of spatial subclonal interactions enhancing the invasive phenotype of pediatric glioma.
Tari, H; Kessler, K; Trahearn, N; Werner, B; Vinci, M; et al. (CELL PRESS, 2022-08-30)Diffuse midline gliomas (DMGs) are highly aggressive, incurable childhood brain tumors. They present a clinical challenge due to many factors, including heterogeneity and diffuse infiltration, complicating disease management. ... -
RACK7 recognizes H3.3G34R mutation to suppress expression of MHC class II complex components and their delivery pathway in pediatric glioblastoma.
Jiao, F; Li, Z; He, C; Xu, W; Yang, G; et al. (AMER ASSOC ADVANCEMENT SCIENCE, 2020-07-01)Histone H3 point mutations have been identified in incurable pediatric brain cancers, but the mechanisms through which these mutations drive tumorigenesis are incompletely understood. Here, we provide evidence that RACK7 ... -
Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial.
Rodriguez Gutierrez, D; Jones, C; Varlet, P; Mackay, A; Warren, D; et al. (AMER ASSOC CANCER RESEARCH, 2020-04-15)PURPOSE: The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma ... -
Recent Advances in ALK2 Inhibitors.
Rooney, L; Jones, C (AMER CHEMICAL SOC, 2021-08-17)Activin receptor-like kinase-2 (ALK2) is a type I bone morphogenetic protein (BMP) receptor which has a role in biological processes that control the development of bone, heart, brain, and other tissue. Gain of function ... -
Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
International Cancer Genome Consortium PedBrain Tumor Project, (NATURE PUBLISHING GROUP, 2016-11-01)Pediatric glioblastoma is one of the most common and most deadly brain tumors in childhood. Using an integrative genetic analysis of 53 pediatric glioblastomas and five in vitro model systems, we identified previously ... -
Repurposing Vandetanib plus Everolimus for the Treatment of ACVR1-Mutant Diffuse Intrinsic Pontine Glioma.
Carvalho, DM; Richardson, PJ; Olaciregui, N; Stankunaite, R; Lavarino, C; et al. (AMER ASSOC CANCER RESEARCH, 2022-02-01)Somatic mutations in ACVR1 are found in a quarter of children with diffuse intrinsic pontine glioma (DIPG), but there are no ACVR1 inhibitors licensed for the disease. Using an artificial intelligence-based platform to ... -
Structural variants shape driver combinations and outcomes in pediatric high-grade glioma.
Dubois, FPB; Shapira, O; Greenwald, NF; Zack, T; Wala, J; et al. (OXFORD UNIV PRESS INC, 2022-06-01)We analyzed the contributions of structural variants (SVs) to gliomagenesis across 179 pediatric high-grade gliomas (pHGGs). The most recurrent SVs targeted MYC isoforms and receptor tyrosine kinases (RTKs), including an ... -
The long non-coding RNA HOTAIR is transcriptionally activated by HOXA9 and is an independent prognostic marker in patients with malignant glioma.
Xavier-Magalhães, A; Gonçalves, CS; Fogli, A; Lourenço, T; Pojo, M; et al. (Impact Journals, LLC, 2018-03-20)The lncRNA HOTAIR has been implicated in several human cancers. Here, we evaluated the molecular alterations and upstream regulatory mechanisms of HOTAIR in glioma, the most common primary brain tumors, and its clinical ... -
The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models.
Martínez-Vélez, N; Garcia-Moure, M; Marigil, M; González-Huarriz, M; Puigdelloses, M; et al. (NATURE PUBLISHING GROUP, 2019-05-28)Pediatric high-grade glioma (pHGG) and diffuse intrinsic pontine gliomas (DIPGs) are aggressive pediatric brain tumors in desperate need of a curative treatment. Oncolytic virotherapy is emerging as a solid therapeutic ... -
The ten-year evolutionary trajectory of a highly recurrent paediatric high grade neuroepithelial tumour with MN1:BEND2 fusion.
Burford, A; Mackay, A; Popov, S; Vinci, M; Carvalho, D; et al. (Springer Science and Business Media LLC, 2018-01-18)Astroblastomas are rare brain tumours which predominate in children and young adults, and have a controversial claim as a distinct entity, with no established WHO grade. Reports suggest a better outcome than high grade ... -
Transcriptomic and epigenetic profiling of 'diffuse midline gliomas, H3 K27M-mutant' discriminate two subgroups based on the type of histone H3 mutated and not supratentorial or infratentorial location.
Castel, D; Philippe, C; Kergrohen, T; Sill, M; Merlevede, J; et al. (BMC, 2018-11-05)Diffuse midline glioma (DMG), H3 K27M-mutant, is a new entity in the updated WHO classification grouping together diffuse intrinsic pontine gliomas and infiltrating glial neoplasms of the midline harboring the same canonical ... -
Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma.
Simpson, AD; Soo, YWJ; Rieunier, G; Aleksic, T; Ansorge, O; et al. (NATURE PUBLISHING GROUP, 2020-03-01)High-grade glioma (HGG) is highly resistant to therapy, prompting us to investigate the contribution of insulin-like growth factor receptor (IGF-1R), linked with radioresistance in other cancers. IGF-1R immunohistochemistry ...